- Beckman Coulter to take over distribution to customers
of a B-type Natriuretic Peptide (BNP) assay, a marker of congestive
heart failure on the company's immunoassay platforms
- This BNP assay for Beckman Coulter immunoassay
analyzers, currently sold as TRIAGE® BNP by Quidel, will now be
sold by Beckman Coulter under the brand name Access BNP
- Laboratories will have continued supply of the
high-quality BNP assay that exclusively runs on Beckman Coulter
immunoassay platforms
- Customers will benefit as the transaction will allow
them to purchase all their testing needs from Beckman
Coulter
BREA, Calif.,
July 26,
2021 /PRNewswire/ -- Beckman Coulter, a global
clinical diagnostics leader, today announced that it has entered
into definitive agreements with Quidel Corporation to obtain all
rights related to the manufacture, distribution, and sale of a BNP
assay for Beckman Coulter analyzers. Under the terms of the
agreements, Quidel will continue to manufacture and supply certain
components to Beckman Coulter related to the assay, and
Beckman Coulter will exclusively manufacture and sell to customers
the BNP assay currently sold as TRIAGE® BNP by Quidel, under the
brand name Access BNP. In addition, the agreements fully resolve
disputes and ongoing litigation between Beckman Coulter and
Quidel.
Beckman Coulter will supply Access BNP globally through the
company's distribution channels and will partner with Quidel to
transition customers, globally, to Access BNP over the coming
months. The schedule per country will be based on local regulations
with the United States and some
other countries transitioning first. Quidel will cease
distribution of the BNP assay after a transition period.
Beckman Coulter's comprehensive cardiac diagnostics menu
provides the tests clinical laboratories need to support informed
clinical decision making. Access BNP joins other Beckman Coulter
cardiovascular diseases (CVD) assays, such as Access hsTnI, the
first FDA-cleared high sensitivity troponin I assay, AccuTnI+3
(Troponin I), CK-MB (Creatine Kinase MB), Myoglobin and
Digoxin.
"We are excited to add Access BNP to Beckman Coulter's line of
high-quality cardiac assays and provide a streamlined customer
experience for our many customers that use this critical assay,"
said Julie Sawyer Montgomery,
president, Beckman Coulter. "Successful management of CVD means
reducing the risk of adverse events by making the right decisions
quickly. Our panel of CVD assays supports advancing care for
cardiac patients."
Cardiovascular diseases account for an estimated 31% of all
deaths worldwide and are the number one cause of death, globally
killing ~17.9 million people each year. Four out of five CVD deaths
are due to heart attacks and strokes, while one third of these
deaths occur prematurely in people under 70 years of age[i]. The
cost of CVDs globally is estimated to rise to $1 trillion USD by 2030[ii]. Clinical
laboratories can support care for patients experiencing, or at risk
for, cardiovascular disease. The speed and accuracy of the
information a clinical laboratory delivers are critical to
improving patient outcomes and reducing the cost of care.
"BNP is a protein secreted by the ventricular musculature in
response to volume or pressure overload on the heart. This is an
important biomarker in the diagnosis of heart failure (HF)[iii] and
left ventricular dysfunction[iv]," said Dr. Anagh Vora, chief
medical officer, Beckman Coulter.
Learn more about Beckman Coulter's cardiovascular disease
solutions at www.beckmancoulter.com/CVD.
About Beckman Coulter
Beckman Coulter is committed to
advancing healthcare for every person by applying the power of
science, technology and the passion and creativity of our teams to
enhance the diagnostic laboratory's role in improving healthcare
outcomes. Our diagnostic systems are used in complex biomedical
testing, and are found in hospitals, reference laboratories and
physician office settings around the globe. Beckman Coulter offers
a unique combination of people, processes and solutions designed to
elevate the performance of clinical laboratories and healthcare
networks. We do this by accelerating care with a menu that matters,
bringing the benefit of automation to all, delivering greater
insights through clinical informatics and unlocking hidden value
through performance partnership. A subsidiary of Danaher
Corporation (NYSE: DHR) since 2011, Beckman Coulter, Inc. is
headquartered in Brea, Calif., and
has more than 11,000 global associates working diligently to make
the world a healthier place.
Forward-Looking Statements
Statements in this release
that are not strictly historical, including any statements
regarding events or developments that we believe or anticipate will
or may occur in the future, are "forward-looking" statements within
the meaning of the federal securities laws. There are a number of
important factors that could cause actual results, developments and
business decisions to differ materially from those suggested or
indicated by such forward-looking statements and you should not
place undue reliance on any such forward-looking statements.
Information regarding the factors that may cause actual results to
differ materially from these forward-looking statements is
available in Danaher Corporation's SEC filings, including Danaher's
2020 Annual Report on Form 10-K and Quarterly Report on Form 10-Q
for the second quarter of 2021. These forward-looking statements
speak only as of the date of this release and except to the extent
required by applicable law, we not assume any obligation to update
or revise any forward-looking statement, whether as a result of new
information, future events and developments or otherwise.
© 2021 Beckman Coulter. All rights reserved. Beckman Coulter,
the stylized logo, and the Beckman Coulter product and service
marks mentioned herein are trademarks or registered trademarks of
Beckman Coulter, Inc. in the United
States and other countries. 2021-8960
i Cardiovascular diseases. (n.d.). Retrieved
May 27, 2021, from Who.int website:
https://www.who.int/health-topics/cardiovascular-diseases
ii Institute for Health Metrics and Evaluation
(IHME). The Global Burden of Diseases, Injuries and Risk Factors
Study 2010 (GBD 2010). Generating Evidence, Guiding Policy
Report
iii Borke, J. Natriuretic Peptides in Congestive
Heart Failure. March 9, 2021.
Medscape. https://emedicine.medscape.com/article/761722-overview
[Accessed: May 27, 2021]
iv Bionda C, Bergerot C, Ardail D,
Rodriguez-Lafrasse C, Rousson R. Plasma BNP and NT-proBNP assays by
automated immunoanalyzers: analytical and clinical study.
Ann Clin Lab Sci. 2006
Summer;36(3):299-306. PMID: 16951271.
Logo -
https://mma.prnewswire.com/media/525815/Beckman_Coulter_Logo.jpg